So sánh phương pháp

	Chỉ số Hoạt động Bệnh Crohn	Bảng câu hỏi ngắn về bệnh viêm ruột (IBDQ-32)
Lĩnh vực	Tiêu hóa học	Tiêu hóa học
Họ	Process / pipeline	Process / pipeline
Năm ra đời	1976	2004
Người khởi xướng	Best, W. R., Becktel, J. M., Singleton, J. W., and Kern, F.	Guyonnet, D., Chassany, O., Ducroc, R., et al.
Loại	Clinician-rated	Self-report
Công trình gốc	Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976). Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 70(3), 439–444.	Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465.
Tên gọi khác	CDAI	IBDQ-32, Short IBDQ
Liên quan	4	4
Tóm tắt	The Crohn's Disease Activity Index (CDAI) is a comprehensive, weighted index for assessing disease activity in Crohn's disease. Developed in 1976 by Best and colleagues for the National Cooperative Crohn's Disease Study, the CDAI integrates eight clinical and laboratory variables into a single score ranging from <150 (remission) to >450 (severe activity). Although more complex than symptom-based tools, the CDAI captures the multidimensional nature of Crohn's disease and remains the reference standard for severe disease assessment.	The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice.